LinkedIn Profile

Access Neumedicines historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:neumedicines 584852 May 30th, 2019 12:00AM Neumedicines Inc. 313 12.00 Open Biotechnology May 30th, 2019 01:44PM May 30th, 2019 01:44PM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Open Open 133 North Altadena Drive Pasadena California US 91107 Health Care Equipment & Services
private:neumedicines 584852 Mar 18th, 2018 12:00AM Neumedicines Inc. 299 12.00 Open Biotechnology Mar 18th, 2018 06:25PM Mar 18th, 2018 06:25PM Open Health Care Equipment & Services
private:neumedicines 584852 Feb 17th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 16th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 15th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 14th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 13th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 12th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 11th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services
private:neumedicines 584852 Feb 10th, 2018 12:00AM Neumedicines Inc. 293 15.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies. Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.